The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients
| Autor: | Klaas Hoekman, Giuseppe Giaccone, Cors van Schaik, Radu A. Manoliu, Matthijs Kater, Jan Hein T.M. van Waesberghe, Martijn R. Meijerink, Hester van Cruijsen |
|---|---|
| Přispěvatelé: | Radiology and nuclear medicine, AGEM - Re-generation and cancer of the digestive system, Medical oncology |
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Haemodynamic response Pleural Neoplasms Administration Oral Contrast Media Perfusion scanning Mediastinal Neoplasms Gefitinib Antineoplastic Combined Chemotherapy Protocols medicine Image Processing Computer-Assisted Humans Radiology Nuclear Medicine and imaging Aged Pelvic Neoplasms medicine.diagnostic_test Dose-Response Relationship Drug business.industry Ultrasound Liver Neoplasms Angiography General Medicine Middle Aged Prognosis Pancreatic Neoplasms medicine.anatomical_structure Injections Intravenous Disease Progression Quinazolines Abdomen Female Radiology business Perfusion Tomography Spiral Computed Artery medicine.drug Follow-Up Studies |
| Zdroj: | European Radiology, 17(7), 1700-1713. Springer Verlag Meijerink, M R, van Cruijsen, H, Hoekman, K, Kater, M, Schaik, C, van Waesberghe, J H T M, Giaccone, G & Manoliu, R A 2007, ' The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients ', European Radiology, vol. 17, no. 7, pp. 1700-1713 . https://doi.org/10.1007/s00330-006-0425-9 |
| ISSN: | 0938-7994 |
| DOI: | 10.1007/s00330-006-0425-9 |
| Popis: | The purpose of this study was to determine the feasibility of dynamic contrast-enhanced perfusion CT (CTP) in evaluating the hemodynamic response of tumors in the chest and abdomen treated with a combination of AZD2171 and gefitinib. Thirteen patients were examined just before and every 4-6 weeks after starting therapy. Following intravenous injection of a contrast agent, dynamic image acquisition was obtained at the level of a selected tumor location. To calculate perfusion, the maximum-slope method was used. Pre-treatment average perfusion for extra-hepatic masses was 84 ml/min/100 g, for liver masses arterial perfusion was 25 ml/min/100 g, and a portal perfusion of 30 ml/min/100 g was found. After the administration of AZD2171 and gefitinib, in extra-hepatic masses an initial decrease in perfusion of 18% was followed by a plateau and in liver masses an initial decrease of 39% within the lesions and of 36% within a rim region surrounding the lesions was followed by a tendency to recovery of hepatic artery flow. In conclusion, CTP is feasible in showing changes of perfusion induced by anti-angiogenic therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink